The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
Buske, C, Hoster, E, Dreyling, M, Eimermacher, H, Wandt, H, Metzner, B, Fuchs, R, Bittenbring, J, Woermann, B, Hohloch, KVolume:
23
Year:
2008
Language:
english
Pages:
9
DOI:
10.1038/leu.2008.261
File:
PDF, 231 KB
english, 2008